Quadrant Capital Group’s Albireo Pharma Inc ALBO Stock Holding History

Quadrant Capital Group’s Portfolio ALBO Stock Details ALBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,845	Closed	-$39.9K	–	2832
2022 Q4	$39.9K	Buy	1,845 +136	+8%	+$2.87K	﹤0.01%	1304
2022 Q3	$33K	Buy	1,709 +1,671	+4,397%	+$34.6K	﹤0.01%	1281
2022 Q2	$1K	Buy	+38	New	+$1K	﹤0.01%	2496

Other funds holding ALBO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Quadrant Capital Group's ALBO Position: Q1 2023 in Review

Quadrant Capital Group sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 1,845 shares — an estimated $39.9K sold.

Quadrant Capital Group first reported a position in ALBO in Q2 2022 and held it in 3 quarters. The position peaked at $39.9K in Q4 2022. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

Quadrant Capital Group reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
Quadrant Capital Group sold 1,845 Albireo Pharma Inc shares in Q1 2023, an estimated $39.9K.
Quadrant Capital Group first reported a position in Albireo Pharma Inc in Q2 2022 and held it in 3 quarters.
Quadrant Capital Group's Albireo Pharma Inc position peaked at $39.9K in Q4 2022.
3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Quadrant Capital Group's 13F filing for Q1 2023, filed 11 May 2023.